Elicera Therapeutics: On the right path - Redeye

Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent share price development, leading to a raised valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1069103/elicera-therapeutics-on-the-right-path?utm_source=finwire&utm_medium=RSS